和黄医药(00013)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

00013 和黄医药

交易中 08-26 11:20:26

27.850

+0.900

+3.34%

最高28.100	最低26.950	成交量109.30万
今开26.950	昨收26.950	日振幅4.27%
总市值242.67亿	流通市值242.67亿	总股本8.71亿
成交额3,029万	换手率0.13%	流通股本8.71亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"00013","market":"HK","secType":"STK","nameCN":"和黄医药","latestPrice":27.85,"timestamp":1724642420018,"preClose":26.95,"halted":0,"volume":1093000,"delay":0,"floatShares":871359720,"shares":871359720,"eps":0.9245255,"marketStatus":"交易中","marketStatusCode":2,"change":0.9,"latestTime":"08-26 11:20:26","open":26.95,"high":28.1,"low":26.95,"amount":30293300,"amplitude":0.042672,"askPrice":27.85,"askSize":500,"bidPrice":27.8,"bidSize":12500,"shortable":3,"etf":0,"ttmEps":-0.3829689387739195,"exchange":"SEHK","tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1724644800000},"adr":0,"listingDate":1624982400000,"adjPreClose":26.95,"openAndCloseTimeList":[[1724635800000,1724644800000],[1724648400000,1724659200000]],"volumeRatio":0.757612,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/00013/wiki","defaultTab":"wiki","newsList":[{"id":"2461559887","title":"和黄医药08月23日遭主力抛售432万元 环比增加248.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2461559887","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461559887?lang=zh_cn&edition=full","pubTime":"2024-08-23 16:15","pubTimestamp":1724400919,"startTime":"0","endTime":"0","summary":"08月23日, 和黄医药股价跌4.94%，报收26.95元，成交金额1.65亿元，换手率0.70%，振幅7.23%，量比0.90。和黄医药今日主力资金净流出432万元，上一交易日主力净流出124万元，今日环比增加248.39%。该股近5个交易日下跌7.19%，主力资金累计净流出627万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流出398万元，其中净流出天数为12日。该股主力净额占比0.02%，港股市场排名2537/2640。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408231615389f4b5d83&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408231615389f4b5d83&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1588","BK1587","00013","BK1191"],"gpt_icon":0},{"id":"2461583741","title":"和黄医药(00013)下跌5.11%，报26.9元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2461583741","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461583741?lang=zh_cn&edition=full","pubTime":"2024-08-23 10:16","pubTimestamp":1724379383,"startTime":"0","endTime":"0","summary":"8月23日，和黄医药(00013)盘中下跌5.11%，截至10:16，报26.9元/股，成交2827.2万元。和黄医药(中国)有限公司是一家专注于全球市场的创新型医药研发企业，主要业务包括研发、生产、营销和经销抗肿瘤药物、处方药和消费保健产品。公司在全球范围内拥有多个上市药物，并在纳斯达克全球精选市场、香港交易所以及伦敦证交所的AIM市场上市。截至2024年中报，和黄医药营业总收入21.79亿元、净利润1.84亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/08/23101642640509.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK4531","BK4007","BK4588","HCM","00013","BK1587","BK1588","BK4585","BK1191"],"gpt_icon":0},{"id":"2461258398","title":"和黄医药盘中异动 早盘股价大跌5.12%报26.900港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2461258398","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461258398?lang=zh_cn&edition=full","pubTime":"2024-08-23 10:16","pubTimestamp":1724379378,"startTime":"0","endTime":"0","summary":"2024年08月23日早盘10时16分，和黄医药股票出现波动，股价大幅跳水5.12%。截至发稿，该股报26.900港元/股，成交量102.59万股，换手率0.12%，振幅5.11%。资金方面，该股资金流入700.59万港元，流出1887.12万港元。和黄医药股票所在的药品行业中，整体跌幅为0.31%。其相关个股中，泰凌医药、君圣泰医药-B、德琪医药-B涨幅较大，振幅较大的相关个股有君圣泰医药-B、艾美疫苗、开拓药业-B，振幅分别为8.89%、7.99%、6.45%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082310161897199b3c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082310161897199b3c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1587","BK1588","BK1191","00013"],"gpt_icon":0},{"id":"2461382705","title":"南向资金8月21日净买入和黄医药46.35万股 连续3日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2461382705","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461382705?lang=zh_cn&edition=full","pubTime":"2024-08-22 09:30","pubTimestamp":1724290205,"startTime":"0","endTime":"0","summary":"8月21日, 南向资金增持和黄医药46.35万股，连续3日增持。截止当日收盘，港股通共持有和黄医药16040.53万股，占流通股18.40%。港股通增持金额前五个股分别为建设银行、中国银行、工商银行、中国移动、快手-W。和黄医药近5个交易日下跌7.10%，港股通累计增持79.89万股；近20个交易日下跌4.25%，港股通累计增持394.16万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408220930099f45c76e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408220930099f45c76e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1587","BK1588","HCM","BK1191","00013"],"gpt_icon":0},{"id":"2459253552","title":"和黄医药盘中异动 急速下跌5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2459253552","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459253552?lang=zh_cn&edition=full","pubTime":"2024-08-16 11:25","pubTimestamp":1723778715,"startTime":"0","endTime":"0","summary":"2024年08月16日早盘11时25分，和黄医药股票出现异动，股价大幅下跌5.01%。截至发稿，该股报29.351港元/股，成交量1328.65万股，换手率1.52%，振幅6.96%。和黄医药股票所在的药品行业中，整体涨幅为0.23%。其相关个股中，联邦制药、康哲药业、四环医药涨幅较大，振幅较大的相关个股有三爱健康集团、泰凌医药、联邦制药，振幅分别为24.66%、10.45%、7.82%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081611251598e351ef&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081611251598e351ef&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1587","BK1588","BK1191","00013"],"gpt_icon":0},{"id":"2459278253","title":"和黄医药(00013)股价下跌5.016%，现价港币$29.35","url":"https://stock-news.laohu8.com/highlight/detail?id=2459278253","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459278253?lang=zh_cn&edition=full","pubTime":"2024-08-16 11:25","pubTimestamp":1723778700,"startTime":"0","endTime":"0","summary":"[下跌股]和黄医药(00013) 股价在上午11:25比前收市价下跌5.016%，现股价为港币$29.35。至目前为止，今日最高价为$31.5，而最低价为$29.35。总成交量为1.329千万股，总成交金额为港币$3.96亿。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205152743541_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205152743541_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2408161784/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["00013","BK1587","BK1588","BK1191"],"gpt_icon":0},{"id":"2459232840","title":"和黄医药(00013)下跌2.43%，报30.15元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2459232840","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459232840?lang=zh_cn&edition=full","pubTime":"2024-08-16 10:13","pubTimestamp":1723774390,"startTime":"0","endTime":"0","summary":"8月16日，和黄医药(00013)盘中下跌2.43%，截至10:13，报30.15元/股，成交3.26亿元。和黄医药(中国)有限公司是一家专注于全球市场的创新型医药研发企业，主要业务包括研发、生产、营销和经销抗肿瘤药物、处方药和消费保健产品。公司在全球范围内拥有多个上市药物，并在纳斯达克全球精选市场、香港交易所以及伦敦证交所的AIM市场上市。截至2024年中报，和黄医药营业总收入21.79亿元、净利润1.84亿元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/08/16101342416358.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["HCM","BK4007","BK4588","00013","BK1191","BK4531","BK1588","BK4585","BK1587"],"gpt_icon":0},{"id":"2459427939","title":"和黄医药(US ADR)上涨2.04%，报19.5美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2459427939","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459427939?lang=zh_cn&edition=full","pubTime":"2024-08-15 21:31","pubTimestamp":1723728688,"startTime":"0","endTime":"0","summary":"8月15日，和黄医药(US ADR)(HCM)开盘上涨2.04%，截至21:31，报19.5美元/股，成交4.47万美元。财务数据显示，截至2024年06月30日，和黄医药(US ADR)收入总额3.06亿美元，同比减少42.64%；归母净利润2580.1万美元，同比减少84.69%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/08/15213142408076.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["BK4588","00013","BK1191","BK4531","HCM","BK4585","BK1587","BK1588","BK4007"],"gpt_icon":0},{"id":"2459143074","title":"和黄医药08月15日遭主力抛售231万元 环比增加260.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2459143074","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459143074?lang=zh_cn&edition=full","pubTime":"2024-08-15 16:16","pubTimestamp":1723709783,"startTime":"0","endTime":"0","summary":"08月15日, 和黄医药股价涨1.98%，报收30.90元，成交金额8926万元，换手率0.33%，振幅5.28%，量比1.48。和黄医药今日主力资金净流出231万元，连续3日净流出，上一交易日主力净流出64万元，今日环比增加260.94%。近一年数据显示，该股主力连续3日净流出后，次日下跌概率为29.41%，平均跌幅为1.66%。该股近5个交易日下跌1.13%，主力资金累计净流出924万元，其中2个交易日为股价上涨时净流出；近20日主力资金累计净流入574万元，其中净流入天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408151617169f2d117e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408151617169f2d117e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1587","BK1588","BK1191","00013"],"gpt_icon":0},{"id":"2459464598","title":"创新药概念普升 百济神州(06160)涨3.14% 机构指出海授权和重磅创新将是行业投资催化剂","url":"https://stock-news.laohu8.com/highlight/detail?id=2459464598","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459464598?lang=zh_cn&edition=full","pubTime":"2024-08-15 10:58","pubTimestamp":1723690691,"startTime":"0","endTime":"0","summary":"国金证券表示，从已披露中报看，创新药企业整体业绩向好趋势明显，百济神州、和黄药业、信达生物等部分药企核心品种销售表现亮丽。上半年以来，创新药鼓励政策陆续落地，此时叠加业绩改善，同时考虑海外流动性变化趋势，该行认为创新药板块有望继续得到市场重视，出海授权和重磅创新将是最大的投资催化剂。","market":"sg","thumbnail":"https://static.szfiu.com/news/20200908/ZDU2M2ViYzhjNGM0OGI0Yjc0M2IyM2I2YWYxMTE5OTk0MjE4MDAxMQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200908/ZDU2M2ViYzhjNGM0OGI0Yjc0M2IyM2I2YWYxMTE5OTk0MjE4MDAxMQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1942341","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348783233.USD","BK1141","BK4548","BK4504","06978","01521","BK4505","02162","BK4139","BK4535","IE00B5MMRT66.SGD","LU0588546209.SGD","09969","IE00BPRC5H50.USD","09995","BK1500","BK4585","BK1583","BK4588","LU0307460666.USD","BK1161","LU2328871848.SGD","LU0348784397.USD","BK1191","LU1969619763.USD","01801","LU2488822045.USD","06160","BK0239","BGNE","09926","BK1588","BK1574","IE00B543WZ88.USD","LU1720050803.USD","BK1576","BK1589","00013","688235","LU0417516571.SGD","159992","LU1794554557.SGD","BK1587","BK4526"],"gpt_icon":0},{"id":"2459468542","title":"南向资金8月14日净买入和黄医药70.75万股 连续3日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2459468542","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459468542?lang=zh_cn&edition=full","pubTime":"2024-08-15 09:31","pubTimestamp":1723685484,"startTime":"0","endTime":"0","summary":"8月14日, 南向资金增持和黄医药70.75万股，连续3日增持。截止当日收盘，港股通共持有和黄医药15960.64万股，占流通股18.30%。和黄医药近5个交易日下跌3.19%，港股通累计增持111.35万股；近20个交易日上涨0.66%，港股通累计增持425.14万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408150939529f2c0c89&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408150939529f2c0c89&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00013","HCM","BK1587","BK1588","BK1191"],"gpt_icon":0},{"id":"2458962555","title":"和黄医药午后涨超3% 机构指呋喹替尼海外销售超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2458962555","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458962555?lang=zh_cn&edition=full","pubTime":"2024-08-12 13:05","pubTimestamp":1723439148,"startTime":"0","endTime":"0","summary":"和黄医药（00013）午后上涨3.21%，现报32.15港元，成交额4658.74万港元。\n　　中信建投指出，肿瘤及免疫业务综合收入持续增长，2024年上半年达到1.687亿美元，同比增长59%。呋喹替尼自23年11月在美国上市以来，表现强劲，销售额达到1.305亿美元。公司在推进全球化和扩展管线方面取得显著进展。下半年索乐匹尼布有望在国内获批，同时赛沃替尼有望于年底在美国提交新药上市申请。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-08-12/doc-incikeri9369681.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-08-12/doc-incikeri9369681.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_sina","symbols":["BK1588","BK1587","00013","BK1191"],"gpt_icon":0},{"id":"2458640826","title":"港股异动 | 和黄医药(00013)盘中涨超4% 呋喹替尼海外销售超预期 索乐匹尼布下半年有望获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2458640826","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458640826?lang=zh_cn&edition=full","pubTime":"2024-08-12 11:51","pubTimestamp":1723434680,"startTime":"0","endTime":"0","summary":"和黄医药(00013)盘中涨超4%，截至发稿，涨2.57%，报31.95港元，成交额4381.72万港元。","market":"sh","thumbnail":"https://img.zhitongcaijing.com/image/20240812/20240812115137_76056.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20240812/20240812115137_76056.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1162796.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["HCM","BK4531","BK4585","BK1191","BK4007","BK4588","BK1588","BK1587","00013"],"gpt_icon":0},{"id":"2458669896","title":"呋喹替尼快速起量 或成下一个10亿美元重磅！和黄、百济等国产新药海外成绩几何？","url":"https://stock-news.laohu8.com/highlight/detail?id=2458669896","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458669896?lang=zh_cn&edition=full","pubTime":"2024-08-11 15:25","pubTimestamp":1723361132,"startTime":"0","endTime":"0","summary":"泽布替尼能在拥挤BTK抑制剂赛道脱颖而出，商业化成绩斐然，依靠的是其差异化优势和快速扩增的丰富适应症。目前，该药已在全球超过70个市场获批，业界期待其未来展现出更优异的市场表现。","market":"sg","thumbnail":"https://img.zhitongcaijing.com/image/20240811/20240811151728_61790.png?x-oss-process=image/format,jpg/quality,Q_80","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20240811/20240811151728_61790.png?x-oss-process=image/format,jpg/quality,Q_80"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1162636.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK4139","00013","BK4588","06978","BK4505","BK1587","BK1588","BK4585","BK1574","LEGN","BK1161","BK1191"],"gpt_icon":0},{"id":"2458889675","title":"和黄医药(00013)出现大手成交34.1万股，成交价$31.575，涉资1.077千万","url":"https://stock-news.laohu8.com/highlight/detail?id=2458889675","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458889675?lang=zh_cn&edition=full","pubTime":"2024-08-09 10:30","pubTimestamp":1723170600,"startTime":"0","endTime":"0","summary":"[大手成交]和黄医药(00013)在上午10:30出现大手成交，成交量为34.1万，成交价为港币$31.575，涉资1.077千万。至目前为止，股价升1.608%，今日最高价为$31.75，而最低价为$31.2，总成交量为73.653万股，总成交金额港币$2.321千万。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180815142908460_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180815142908460_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2408094001/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1588","00013","BK1191","BK1587"],"gpt_icon":0},{"id":"2457936821","title":"和黄医药08月08日主力资金流入121万元 连续3日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2457936821","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457936821?lang=zh_cn&edition=full","pubTime":"2024-08-08 16:16","pubTimestamp":1723104974,"startTime":"0","endTime":"0","summary":"08月08日, 和黄医药股价跌0.64%，报收31.10元，成交金额5151万元，换手率0.19%，振幅3.04%，量比0.41。和黄医药今日主力资金净流入121万元，连续3日净流入，上一交易日主力净流入40万元，今日环比增加202.50%。近一年数据显示，该股主力连续3日净流入后，次日上涨概率为58.33%，平均涨幅为4.15%。该股近5个交易日上涨5.94%，主力资金累计净流入878万元，其中2个交易日为股价下跌时净流入；近20日主力资金累计净流入3964万元，其中净流入天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408081616519f19ce35&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408081616519f19ce35&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","BK1587","BK1588","00013"],"gpt_icon":0},{"id":"2457679998","title":"【券商聚焦】财通证券维持和黄医药(00013)“增持”评级 料海外收入不断增长 成长确定性较高","url":"https://stock-news.laohu8.com/highlight/detail?id=2457679998","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457679998?lang=zh_cn&edition=full","pubTime":"2024-08-07 15:24","pubTimestamp":1723015444,"startTime":"0","endTime":"0","summary":"金吾财讯 | 财通证券发研报指，和黄医药 2024H1总收入为3.1亿美元。该行表示，呋喹替尼在取得美国患者接受度的同时，于2023年11月16日迅速纳入2023年《NCCN结肠癌临床实践指南》和2023年《NCCN直肠癌临床实践指南》，亦获结直肠癌领域的另外数个主要治疗指南推荐。这些都将继续推动呋喹替尼在医生和患者中的认知度和使用。预计2025年实现盈利，公司海外收入不断增长，成长确定性较高，维持“增持”评级。","market":"other","thumbnail":"https://static.szfiu.com/news/20210810/ZDJiMDMxMTQ0NzYwOTE1MWRjNWM4ZTAxY2ZiMjQwNjM2MTY3ODIyMw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/ZDJiMDMxMTQ0NzYwOTE1MWRjNWM4ZTAxY2ZiMjQwNjM2MTY3ODIyMw==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1941847","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00013","601108","HCM"],"gpt_icon":0},{"id":"2457007970","title":"成分股Castle Biosciences收涨13.96%，Exscientia ADR涨13.38%，和黄医药（HCM）涨10.","url":"https://stock-news.laohu8.com/highlight/detail?id=2457007970","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457007970?lang=zh_cn&edition=full","pubTime":"2024-08-07 05:37","pubTimestamp":1722980247,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"live_wallstreetcn","url":"https://wallstreetcn.com/live/a-stock","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wallstreetcn.com/live/a-stock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_wallstreetcn","symbols":["BK1587","BK4531","BK4588","00013","EXAI","BK1191","BK4139","TBPH","BK1588","HCM","BK4585","LENZ","LXRX","BK4007"],"gpt_icon":0},{"id":"2457909350","title":"【和黄医药(00013.HK)授出认股权计划项下的认股权及长期奖励计划项下的奖励】智通财经APP讯，和黄医药(00013.","url":"https://stock-news.laohu8.com/highlight/detail?id=2457909350","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457909350?lang=zh_cn&edition=full","pubTime":"2024-08-06 17:15","pubTimestamp":1722935732,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4007","BK4585","BK1587","BK4531","00013","BK4588","HCM","BK1191","BK1588"],"gpt_icon":0},{"id":"2457090958","title":"和黄医药(00013)授出认股权计划项下的认股权及长期奖励计划项下的奖励","url":"https://stock-news.laohu8.com/highlight/detail?id=2457090958","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457090958?lang=zh_cn&edition=full","pubTime":"2024-08-06 17:15","pubTimestamp":1722935732,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和黄医药(00013)发布公告，该公司已于2024年8月5日授出和黄医药于2015年采纳的认股权计划项下的认股权及和黄医药于2015年采纳的长期奖励计划项下的奖励。和黄医药向苏慰国(执行董事、首席执行官兼首席科学官)(即根据英国市场滥用条例履行管理职责的人士)授出其认股权计划项下的认股权，惟须受表现目标所规限;在承授人接纳的前提下，以供认购公司股本中合共140.58万股每股面值0.10美元的普通股。和黄医药向其1名雇员授出其认股权计划项下的认股权，在承授人接纳的前提下，以供认购公司股本中合共20万股普通股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1160584.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4007","00013","BK4588","HCM","BK1587","BK1588","BK1191","BK4531","BK4585"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.hutch-med.com","stockEarnings":[{"period":"1week","weight":-0.0771},{"period":"1month","weight":-0.0833},{"period":"3month","weight":-0.0926},{"period":"6month","weight":0.0889},{"period":"1year","weight":0.182},{"period":"ytd","weight":-0.061}],"compareEarnings":[{"period":"1week","weight":0.0104},{"period":"1month","weight":0.0174},{"period":"3month","weight":-0.0536},{"period":"6month","weight":0.053},{"period":"1year","weight":-0.0329},{"period":"ytd","weight":0.0331}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"和黄医药（中国）有限公司（原名：和黄中国医药科技有限公司）是一家主要从事药品制造及销售的投资控股公司。连同其附属公司，该公司通过两个分部经营业务。肿瘤及免疫业务分部从事发现、开发和商业化用于治疗癌症和免疫性疾病的靶向疗法和免疫疗法，包括涵盖药物发现、开发、生产及监管职能的研发活动，以及支持研发业务的行政活动，还包括通过研发活动开发的药物的销售、推广、生产及分销。其他业务分部从事其他商业化业务，包括其他处方药物及非处方药物以及消费保健品的销售、推广、生产及分销。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.130873},{"month":2,"riseRate":0.666667,"avgChangeRate":0.058734},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.131658},{"month":4,"riseRate":0.666667,"avgChangeRate":0.04977},{"month":5,"riseRate":0,"avgChangeRate":-0.194502},{"month":6,"riseRate":0.333333,"avgChangeRate":0.018958},{"month":7,"riseRate":1,"avgChangeRate":0.135989},{"month":8,"riseRate":0.25,"avgChangeRate":-0.062094},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.081182},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.003665},{"month":11,"riseRate":0.666667,"avgChangeRate":0.265429},{"month":12,"riseRate":0.666667,"avgChangeRate":0.027237}],"exchange":"SEHK","name":"和黄医药","nameEN":"HUTCHMED"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"和黄医药(00013)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供和黄医药(00013)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"和黄医药,00013,和黄医药股票,和黄医药股票老虎,和黄医药股票老虎国际,和黄医药行情,和黄医药股票行情,和黄医药股价,和黄医药股市,和黄医药股票价格,和黄医药股票交易,和黄医药股票购买,和黄医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"和黄医药(00013)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供和黄医药(00013)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}